Fresenius Medical Care AGMEX:FME N 50 EBITDA Margin % is 16.56% as of Mar. 2026, which is 10% below its 10-year median of 18.43. GuruFocus rates MEX:FME N with a GF Score™ of 50/100 and a GF Value™ of MXN1,677.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Fresenius Medical Care AG ranks better than 69.16% on this metric.
Fresenius Medical Care AG (MEX:FME N) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fresenius Medical Care AG EBITDA Margin % Related Terms
Fresenius Medical Care AG EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:FME N vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Fresenius Medical Care AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius Medical Care AG EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fresenius Medical Care AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG (MEX:FME N) has a EBITDA Margin % of 16.56% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fresenius Medical Care AG and its competitors. This is 10% below median its historical median of 18.43. Over the past decade, Fresenius Medical Care AG's EBITDA Margin % has ranged from 16.50 to 24.02. According to the industry distribution chart, Fresenius Medical Care AG ranks #206 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 30.8%.
Is Fresenius Medical Care AG's EBITDA Margin % too high?
Fresenius Medical Care AG's current EBITDA Margin % of 16.56% is 10% below median its 10-year median of 18.43. Over the past 10 years, this metric has ranged from a low of 16.50 to a high of 24.02. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Fresenius Medical Care AG's value of 16.56% is 62.2% above this industry median. Based on the distribution chart, Fresenius Medical Care AG ranks #206 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Fresenius Medical Care AG has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius Medical Care AG ranks #206 out of 668 companies for EBITDA Margin %. This puts Fresenius Medical Care AG in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Fresenius Medical Care AG's value of 16.56% is 62.2% above this benchmark. Historically, Fresenius Medical Care AG's own EBITDA Margin % has ranged from 16.50 to 24.02 over the past decade. While the company's 10-year median is 18.43 vs. the industry median of 10.21, Fresenius Medical Care AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius Medical Care AG's current EBITDA Margin % of 16.56% is 62.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fresenius Medical Care AG and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius Medical Care AG's current EBITDA Margin % is 16.56%, which is 10% below median its own 10-year median of 18.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Based on GuruFocus' analysis, Fresenius Medical Care AG (MEX:FME N) is currently considered Possible Value Trap. The stock's GF Value™ is MXN1,677.25, compared to a current price of MXN778.14 — trading 53.6% below its estimated fair value. The current EBITDA Margin % is 16.56%, which is 10% below median its 10-year median of 18.43 and 62.2% above the Healthcare Providers & Services industry median of 10.21. Fresenius Medical Care AG's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fresenius Medical Care AG (MEX:FME N), the current EBITDA Margin % is 16.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius Medical Care AG (MEX:FME N) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be undervalued.
The current stock price of MXN778.14 is trading 53.6% below its estimated GF Value™ of MXN1,677.25.
GuruFocus considers Fresenius Medical Care AG to be Possible Value Trap.
Key valuation signals for MEX:FME N:
EBITDA Margin %: 16.56% (10% below median its 10-year median of 18.43)
GF Value™: MXN1,677.25 vs. price of MXN778.14 (53.6% below fair value)
Industry Position: 62.2% above the Healthcare Providers & Services median (#206 of 668)
No single metric tells the full story. See the MEX:FME N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
50GF Score
Get the complete analysis for MEX:FME N
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:FME N has been successfully added to your 
